BioMarin Pharmaceutical Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2008 | $-9.2M | $-65.5M | $56.4M | $28.3M |
| FY2009 | $87.7M | $-2.1M | $89.8M | $36.0M |
| FY2010 | $18.7M | $-30.7M | $49.5M | $38.4M |
| FY2011 | $18.4M | $-54.8M | $73.2M | $43.9M |
| FY2012 | $17.6M | $-27.0M | $44.6M | $47.3M |
| FY2013 | $-59.6M | $-124.8M | $65.2M | $64.4M |
| FY2014 | $-70.4M | $-187.5M | $117.1M | $86.4M |
| FY2015 | $-219.5M | $-447.2M | $227.7M | $111.5M |
| FY2016 | $-227.8M | $-376.2M | $148.4M | $134.6M |
| FY2017 | $-8.8M | $-208.0M | $199.2M | $140.3M |
| FY2018 | $20.2M | $-124.4M | $144.6M | $148.8M |
| FY2019 | $48.3M | $-96.8M | $145.0M | $159.9M |
| FY2020 | $85.4M | $-28.9M | $114.3M | $189.7M |
| FY2021 | $304.5M | $209.0M | $95.6M | $197.3M |
| FY2022 | $175.9M | $54.9M | $121.0M | $196.3M |
| FY2023 | $159.3M | $62.6M | $96.7M | $207.1M |
| FY2024 | $572.8M | $487.4M | $85.4M | $201.6M |
| FY2025 | $828.0M | $725.0M | $103.0M | $181.4M |